Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Intravenous (IV) atezolizumab is approved for non–small cell lung and other cancers. Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase, a permeation enhancer for SC dispersion and absorption, is being developed to improve treatment options, reduce burden, and increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Felip, Enriqueta, Burotto, Mauricio, Zvirbule, Zanete, Herraez‐Baranda, Luis A., Chanu, Pascal, Kshirsagar, Smita, Maiya, Vidya, Chan, Phyllis, Pozzi, Emanuela, Marchand, Mathilde, Monchalin, Marion, Tanaka, Kunihiko, Tosti, Nadia, Wang, Bei, Restuccia, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518371/
https://www.ncbi.nlm.nih.gov/pubmed/33788415
http://dx.doi.org/10.1002/cpdd.936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518371/
https://www.ncbi.nlm.nih.gov/pubmed/33788415
http://dx.doi.org/10.1002/cpdd.936

Ejemplares similares